- Open Access
Correction: A novel approach for relapsed/refractory FLT3mut+acute myeloid leukaemia: synergistic effect of the combination of bispecific FLT3scFv/NKG2D-CAR T cells and gilteritinib
Molecular Cancer volume 21, Article number: 134 (2022)
Correction: Mol Cancer 21, 66 (2022)
Following publication of the original article , the authors identified minor errors in Figs. 3, 4, 5 and Additional file 5: Figure S5, and Additional file 14: Table S4; specifically:
Fig. 3B: 'Control' panel was originally a duplicate of the Giliteritinib panel; this has been replaced by the correct images
Fig. 4A: The ordinate label was incorrectly listed as 'FSC'; the correct listing is 'count'
Fig. 4B and Fig. 4C: the column color of the statistical histograms in did not originally correspond to the legend color; this has been corrected
Fig. 5D: incorrect images were used for the control group and +G group (rows 1 and 2); these have been replaced by the correct images
Additional file 5: Figure S5A: incorrect image used for the MICB band; this has been replaced with the correct image
Additional file 14: Table S4: The sequences of forward/reverse primers for Rel A, Rel B and c-Rel were found to be erroneously completed; this has been corrected
The corrected figures and table are given here. The correction does not have any effect on the final conclusions of the paper. The original article has been corrected.
Li K, Wu H, Pan Wy, et al. A novel approach for relapsed/refractory FLT3mut+ acute myeloid leukaemia: synergistic effect of the combination of bispecific FLT3scFv/NKG2D-CAR T cells and gilteritinib. Mol Cancer. 2022;21:66. https://doi.org/10.1186/s12943-022-01541-9.
Additional file 5: Figure S5A.
The transcriptional role of NF-κB2 in NKG2DL expression.
Additional file 14: Table S4.
The sequences of forward/reverse primers for target genes.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Li, Kx., Wu, Hy., Pan, Wy. et al. Correction: A novel approach for relapsed/refractory FLT3mut+acute myeloid leukaemia: synergistic effect of the combination of bispecific FLT3scFv/NKG2D-CAR T cells and gilteritinib. Mol Cancer 21, 134 (2022). https://doi.org/10.1186/s12943-022-01566-0